Maria Horton
Nurse Practitioner · Saginaw, MINPI 1528519956
Payments from drug & device makers
Across 120 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$419
- Otsuka America Pharmaceutical, Inc.$249
- Lundbeck LLC$242
- AbbVie$225
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$117
- Vanda Pharmaceuticals Inc.$114
- plus $644 from 13 others
What the payments were for
- Food & beverage$2,010100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 17 | $419 |
| Otsuka America Pharmaceutical, Inc. | 18 | $249 |
| Lundbeck LLC | 24 | $242 |
| AbbVie(2 entities) | 14 | $225 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $117 |
| Vanda Pharmaceuticals Inc. | 5 | $114 |
| Axsome Therapeutics, Inc. | 5 | $100 |
| E.r. Squibb & Sons, L.L.C. | 5 | $94 |
| Johnson & Johnson | 5 | $92 |
| Indivior Inc. | 4 | $82 |
| Teva Pharmaceuticals USA, Inc. | 3 | $69 |
| Neurocrine Biosciences, Inc. | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $15 |
How this compares
$2,010 in reported general payments places this provider in the 85th percentile of 3,351 nurse practitioner providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 26 | $35,354 |
| VraylarCariprazine Hcl | 19 | $26,455 |
| TrintellixVortioxetine Hydrobromide | 34 | $19,971 |
| Lurasidone Hcl | 26 | $6,485 |
| Aripiprazole | 101 | $3,939 |
| Paliperidone ErPaliperidone | 32 | $2,923 |
| Quetiapine Fumarate | 117 | $2,618 |
| Atomoxetine Hcl | 18 | $2,363 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 57 | $2,198 |
| Duloxetine Hcl | 101 | $2,130 |
| Buspirone Hcl | 130 | $1,810 |
| Trazodone Hcl | 134 | $1,805 |
| Naltrexone Hcl | 19 | $1,584 |
| Amitriptyline Hcl | 88 | $1,550 |
| Divalproex Sodium | 19 | $1,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $249 | $35,35426 claims |
| AbbVieVraylar | $225 | $26,45519 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $33 | $19,97134 claims |
| Lilly USA, LLCOlanzapine | $26 | $76340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Saginaw
- Jessica HerekSaginaw$13K
- Davida KrugerDetroit$1.8M
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Elizabeth KirshnerAnn Arbor$119K
- Lisa Astalos ChismWoodhaven$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.